

Notice of Public Hearing Placement of Chemicals in Schedule I

Pursuant to subsection D of § 54.1-3443, the Board of Pharmacy is giving notice of a public hearing to consider placement of chemical substances in Schedule I of the Drug Control Act. The public hearing will be conducted at **9:00 a.m. on June 21, 2018** at the Perimeter Center, 9960 Mayland Drive, Suite 201, Richmond, VA 23233. Public comment may also be submitted electronically or in writing prior to June 7, 2018 to Caroline Juran, Executive Director of the Board of Pharmacy to caroline.juran@dhp.virginia.gov.

The Virginia Department of Forensic Science (DFS) has identified eight (8) chemical compounds for recommended inclusion into the Code of Virginia. A brief description and chemical name for each compound is as follows:

The following compound is classified as a research chemical. Compounds of this type have been placed in Schedule I (§ 54.1-3446(3)) in previous legislative sessions.

1. **2,5-dimethoxy-4-chloroamphetamine (other name: DOC)**, its optical, position, and geometric isomers, salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

The following compounds are powerful synthetic opioids. Compounds of this type have been placed in Schedule I (§ 54.1-3446(1)) in previous legislative sessions.

2. **N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (other name: Ocfentanil)**, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.
3. **N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (other name: 4-methoxybutyrylfentanyl)**, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.
4. **N-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name: Isobutyryl fentanyl)**, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.
5. **N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarboxamide (other name: Cyclopentyl fentanyl)**, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.
6. **N-phenyl-N-(1-methyl-4-piperidinyl)-propanamide (other name: N-methyl norfentanyl)**, its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation.

The following compound is classified as a cannabimimetic agent. Compounds of this type have been placed in Schedule I (§ 54.1-3446(6)) in previous legislative sessions.

7. **1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide (other name: 4-cyano CUMYL-BUTINACA)**, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

The following compound is classified as a benzodiazepine, which is a central nervous system depressant. Flualprazolam has no accepted medical use in the United States. Other compounds of this type have been placed in Schedule I (§ 54.1-3446(4)).

8. **Flualprazolam**, its salts, isomers and salts of isomers whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation.

Notice of Public Hearing Scheduling/De-scheduling to Conform to DEA Actions

Pursuant to subsection E of § 54.1-3443, the Board of Pharmacy is giving notice of a public hearing to consider scheduling or de-scheduling certain drugs in the Virginia Drug Control Act. The public hearing will be conducted at **9:00 a.m. on June 21, 2018** at the Perimeter Center, 9960 Mayland Drive, Suite 201, Richmond, VA 23233.

In order to conform the Drug Control Act to recent scheduling changes enacted by the Drug Enforcement Administration, the Board will:

- 1) Add MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) to Schedule I;
- 2) Add Dronabinol [(-)-delta-9-*trans* tetrahydrocannabinol] in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration to Schedule II; and
- 3) Removes naldemedine from Schedule II.